Menu
Recruiting NCT05817929

Angiopoietin and Adverse Outcomes in Cardiac Surgery

No phase Interventional Cardiac Surgery Acute Kidney Injury

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: blood sample.
Who it may be relevant to
Registry conditions: Cardiac Surgery, Acute Kidney Injury. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Angiopoietin Dysregulation to Predict Adverse Outcomes in Cardiac Surgery: the Prospective

Overview

Cardiac surgery and cardiopulmonary bypass can lead to systemic organ failure trough excess inflammation and endothelial injury. The angiopoietin family represented by angiopoietin 1 and 2 can reflect endothelial injury by a decrease in angiopoietin 1 and an increase in angiopoietin 2. The investigators hypothesized that angiopoietin dysregulation could reflect organ failure related to cardiac surgery. The purpose of this project is to assess the association between angiopoietin dysregulation and adverse outcomes on cardiac surgery.

Interventions

  • Other blood sample
    5 ml blood sample will be withdrawn at the surgery start and at the surgery end

Primary outcome measures

  • Correlation between abnormal angiopoietin 1 concentration (ng/ml) and number of major cardiovascular event [Time frame: 28 days]
  • correlation between occurence of abnormal angiopoietin 2 concentration (ng/ml) and occurence of major cardiovascular event [Time frame: 28 days]
Secondary outcome measures (8)
  • Correlation between abnormal angiopoietin 1 concentration (ng/ml) and number of postoperative pulmonary complications [Time frame: 28 days]
  • Correlation between abnormal angiopoietin 2 concentration (ng/ml) and number of postoperative pulmonary complications [Time frame: 28 days]
  • Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality at 3 months [Time frame: 3 months]
  • Correlation between abnormal angiopoietin 2 concentration (ng/ml) and mortality at 3 months [Time frame: 3 months]
  • Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality at 6 months [Time frame: 6 months]
  • Correlation between occurence of abnormal angiopoietin 2 concentration (ng/ml) and mortality at 6 months [Time frame: 6 months]
  • Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality rate at 12 months [Time frame: 12 months]
  • Correlation between abnormal angiopoietin 2 concentration (ng/ml) and mortality rate at 12 months [Time frame: 12 months]

Eligibility criteria

Inclusion criteria

  • adult patient scheduled for cardiac surgery under cardiopulmonary bypass

Exclusion criteria

  • patient less than 18 years old,
  • redo surgery,
  • urgent surgery,
  • endocarditis,
  • aortic root repair surgery
  • aortic dissection
  • heart beating surgery,
  • heart transplantation

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Other

Study locations

France · 1 center
  • CHU Amiens Picardie — Amiens

Identifiers

NCT: NCT05817929 · PI2023_843_0015

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗